Case Report: Multi-cancer early detection utilizing blood-based genomics: Single-institution case series of novel cancer screening
Our institutional experience demonstrates the feasibility of MCED testing. Additional prospective randomized clinical trials are needed before widespread adoption. The information and data included in this manuscript was previously presented as a poster (e612 Poster Q&A Sessions) at the 2024 American Society for Radiation Oncology Annual Meeting.
Authors
- Daniel Potts (ORCID: https://orcid.org/0000-0003-3651-4364)
- Francisco de Asís
- Jason C. Burton (ORCID: https://orcid.org/0000-0002-0729-9215)
- Nima Nabavizadeh (ORCID: https://orcid.org/0000-0001-9152-8262)
- Somya Khare
- Mason J. Stewart-McLellan
- Tiffani L. Howard
- Solomon Mekonnen
Institutions
- Midwestern University (US)
- Oregon Health & Science University (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.3389/fonc.2025.1637999
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00